Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, The Mark Foundation Partner for Oncology | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, The Mark Foundation Partner for Oncology

The Mark Foundation will provide research funding to Evotec to discover and develop first-in-class therapeutics in oncology

By: Betsy Louda

, Contract Pharma

Evotec AG and The Mark Foundation for Cancer Research have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. 

 
The collaboration, for an initial period of two years, is based on Evotec’s new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. This approach is expected to deliver highly potent and more durable treatments for both clinically validated and novel immuno-oncology targets.
 
Under the terms of the agreement, The Mark Foundation will provide research funding to Evotec. Evotec will in turn be responsible for subsequent partnering of the programs and/or the platform. The Mark Foundation will use its share of potential financial returns to expand its grant portfolio.
 
Dr Cord Dohrmann, chief scientific officer of Evotec, said, “Evotec is very pleased to partner with The Mark Foundation, who is truly dedicated to accelerating potential cures for cancer by investing into promising new technology platforms and well-differentiated drug discovery projects. The support from The Mark Foundation allows us to engage multiple targets through a novel mechanism of action which is expected to deliver more potent but also more durable drug candidates.”
 
Dr Michele Cleary, chief executive officer of The Mark Foundation, said, “Our partnership with Evotec fits well with our goal of advancing early-stage therapeutic innovation. We are excited about the prospect of expanding the options for targeting some of the most challenging but important molecules in cancer immunology.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics